shutterstock_1532109092_sundry_photography

Sundry Photography / Shutterstock.com

7 October 2021Medtech

Federal Circuit hands victory to Snyders over heart valve patent

The US Court of Appeals for the Federal Circuit has held that claims of a patent covering an artificial heart valve were erroneously held to be unpatentable by the US Patent Trial and Appeal Board (PTAB), in a blow to a medical device company owned by Abbott Laboratories.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Federal Circuit resuscitates Snyder’s heart valve patent

16 October 2020 A medical device company, St. Jude Medical, part of Abbott Laboratories, failed in its bid to invalidate a patent for an artificial heart valve at the US Court of Appeals for the Federal Circuit yesterday, Thursday, October 15.

Snyders revives patent claims against St Jude Medical

25 March 2021 Snyders Heart Valve has been successful in reviving patent claims in an on-going dispute against St Jude Medical.

More on this story

Snyders revives patent claims against St Jude Medical

25 March 2021 Snyders Heart Valve has been successful in reviving patent claims in an on-going dispute against St Jude Medical.

Federal Circuit resuscitates Snyder’s heart valve patent

16 October 2020 A medical device company, St. Jude Medical, part of Abbott Laboratories, failed in its bid to invalidate a patent for an artificial heart valve at the US Court of Appeals for the Federal Circuit yesterday, Thursday, October 15.

More on this story

Snyders revives patent claims against St Jude Medical

25 March 2021 Snyders Heart Valve has been successful in reviving patent claims in an on-going dispute against St Jude Medical.

Federal Circuit resuscitates Snyder’s heart valve patent

16 October 2020 A medical device company, St. Jude Medical, part of Abbott Laboratories, failed in its bid to invalidate a patent for an artificial heart valve at the US Court of Appeals for the Federal Circuit yesterday, Thursday, October 15.

More features

Sandoz lands reduced antitrust award of $70m

New president’s to-do list: Patent bills, non-competes, USPTO director?

Sanofi subsidiary fends off $450m trade secrets case

Regulatory expert joins White & Case

Teva faces $500m fine for antitrust breaches over MS drug

UK Budget: A missed opportunity?

Pfizer infringed haemophilia therapy patent, says court

Cooley adds ex-Gowling partner